3D Co-Culture of Pluripotent Stem Cells for Muscle Stem Cell Expansion

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing muscle stem cells induce terminal commitment to myogenic differentiation, leading to poor long-term engraftment potential and inefficient treatment of muscle diseases such as muscular dystrophy and sarcopenia.

Innovation Solution

A 3D cell culture method involving co-culturing pluripotent stem cells with embryonic fibroblast cells and endothelial cells in specific ratios to maintain uncommitted muscle stem cells that express stem cell markers like Pax7 but remain negative for commitment markers like Myf5, mimicking the natural muscle stem cell niche.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional 2D culture methods are used to expand muscle stem cells, then cell proliferation is achieved, but terminal commitment to myogenic differentiation occurs leading to loss of stemness

Engineering Contradiction:
Improvecell proliferationVSAvoidstem cell uncommitted state
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent transitions from conventional 2D culture to 3D spheroid culture system. This dimensional change creates a more physiologically relevant microenvironment that maintains stem cell uncommitted state while allowing proliferation. The 3D architecture enables better nutrient diffusion, cell-cell interactions, and mimics the in vivo niche conditions that prevent premature differentiation.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The patent introduces endothelial cells as intermediary components in the co-culture system. These endothelial cells form a vascular-like niche that secretes factors (such as VEGF, FGF) which maintain muscle stem cell quiescence and prevent terminal differentiation. The endothelial cells act as mediators between the muscle stem cells and the culture environment, providing signals that preserve stemness during expansion.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If muscle stem cells are expanded in conventional culture, then sufficient cell numbers are obtained, but long-term engraftment potential is impaired due to differentiation commitment

Engineering Contradiction:
Improvenumber of muscle stem cellsVSAvoidlong-term engraftment potential
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent performs preliminary differentiation of pluripotent stem cells into muscle progenitors before the expansion phase. This preliminary action establishes the correct cell lineage and prepares the cells for subsequent controlled expansion. By pre-differentiating to a committed progenitor state and then maintaining them in an uncommitted state through 3D co-culture, the method ensures both sufficient numbers and retained engraftment potential.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent changes multiple cultural parameters simultaneously: transitioning from 2D to 3D geometry, adding endothelial cell co-culture, optimizing oxygen tension, and adjusting growth factor concentrations. These parameter changes collectively create a niche-like environment that allows cell expansion while preserving the biological properties necessary for long-term engraftment and preventing terminal differentiation.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If pluripotent stem cells are differentiated towards muscle lineage, then muscle progenitors are generated, but premature commitment to fusion into fibres occurs

Engineering Contradiction:
Improvegeneration of muscle progenitorsVSAvoidtime in uncommitted state
Core Design Contradiction:
ProductivityVSDuration of action of moving object

Solution Approach 1:

The patent establishes a continuous culture system where muscle progenitors are generated from pluripotent stem cells and then maintained in an uncommitted state through ongoing 3D co-culture with endothelial cells. This continuous provision of niche signals (growth factors, cell-cell contacts, 3D architecture) sustains the progenitors in a proliferative but undifferentiated state for extended periods, preventing premature commitment to fibre formation while maintaining muscle lineage identity.

Inventive Principle:
Principle #20Continuity of useful action

Data Source

PatentEP3541929B1In vitro production of muscle stem cells
Publication Date: 2023.03.22 SOCIETE DES PRODUITS NESTLE SA
  • EP3541929B1 patent drawingFigure 1
  • EP3541929B1 patent drawingFigure 2A~2B
  • EP3541929B1 patent drawingFigure 3A

AI summary

An in vitro method of producing a population of muscle stem cells comprising co-culturing pluripotent stem cells, embryonic fibroblast cells and endothelial cells in 3D cell culture.